Tag: Shifa

Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

Coronary/Structural Heart by 0 comments

– Collaboration with Xontogeny provides funding and key advisory support for early development – MALVERN, Pa.–(BUSINESS WIRE)–Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21, to treat dyslipidemia, today […]

Continue Reading →

Shifa Biomedical Corporation Presents Preclinical Data on P-21, a Novel Orally Active PSCK9 Antagonist, at the American Heart Association (AHA) Meeting, Scientific Sessions 2018

Coronary/Structural Heart by 0 comments

CHICAGO, Nov. 12, 2018 (GLOBE NEWSWIRE) — Shifa Biomedical Corporation (Shifa), a drug discovery biopharmaceutical company focused on developing novel agents to treat cardiovascular disease and hypercholesteremia, today announced exciting preclinical data involving the company’s pre-clinical candidate, P-21, which interferes […]

Continue Reading →